Abstract
Over the last few years, several new agents have been under evaluation in preclinical studies and clinical trials, showing promise in treating chronic lymphocytic leukemia (CLL). Among these agents, monoclonal antibodies (mAbs) such as rituximab and alemtuzumab have changed the natural course of the disease. Nowadays there are several new promising monoclonal antibodies under investigation against the CD20, CD23, CD37 and CD40 molecules. Application of newer monoclonal antibodies represents an area of ongoing clinical research in CLL.
MeSH terms
-
Antibodies, Monoclonal / immunology
-
Antibodies, Monoclonal / therapeutic use*
-
Antigens, CD / chemistry
-
Antigens, CD / metabolism
-
Antigens, CD20 / chemistry
-
Antigens, CD20 / metabolism
-
Antigens, Neoplasm / chemistry
-
Antigens, Neoplasm / metabolism
-
Antineoplastic Agents / immunology
-
Antineoplastic Agents / therapeutic use*
-
CD40 Antigens / antagonists & inhibitors
-
CD40 Antigens / metabolism
-
CD52 Antigen
-
Glycoproteins / antagonists & inhibitors
-
Glycoproteins / metabolism
-
Humans
-
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
-
Receptors, IgE / antagonists & inhibitors
-
Receptors, IgE / metabolism
-
Tetraspanins
Substances
-
Antibodies, Monoclonal
-
Antigens, CD
-
Antigens, CD20
-
Antigens, Neoplasm
-
Antineoplastic Agents
-
CD37 protein, human
-
CD40 Antigens
-
CD52 Antigen
-
CD52 protein, human
-
Glycoproteins
-
Receptors, IgE
-
Tetraspanins